A comparative study of receptor interactions between SARS-CoV and SARS-CoV-2 from molecular modeling

Hien T. T. Lai1 · Ly H. Nguyen1 · Anh D. Phan2 · Agata Kranjc3,4,5 · Toan T. Nguyen1 · Duc Nguyen-Manh6

Received: 5 April 2022 / Accepted: 16 July 2022 / Published online: 8 September 2022
© The Author(s) 2022

Abstract
The pandemic of COVID-19 severe acute respiratory syndrome, which was fatal for millions of people worldwide, triggered the race to understand in detail the molecular mechanisms of this disease. In this work, the differences of interactions between the SARS-CoV/SARS-CoV-2 Receptor binding domain (RBD) and the human Angiotensin Converting Enzyme 2 (ACE2) receptor were studied using in silico tools. Our results show that SARS-CoV-2 RBD is more stable and forms more interactions with ACE2 than SARS-CoV. At its interface, three stable binding patterns are observed and named red-K31, green-K353 and blue-M82 according to the central ACE2 binding residue. In SARS-CoV instead, only the first two binding patches are persistently formed during the MD simulation. Our MM/GBSA calculations indicate the binding free energy difference of about 2.5 kcal/mol between SARS-CoV-2 and SARS-CoV which is compatible with the experiments. The binding free energy decomposition points out that SARS-CoV-2 RBD–ACE2 interactions of the red-K31 (−23.5 ± 0.2 kcal/mol) and blue-M82 (−9.1 ± 0.1 kcal/mol) patterns contribute more to the binding affinity than in SARS-CoV (−1.8 ± 0.02 kcal/mol for red-K31), while the contribution of the green-K353 pattern is very similar in the two strains (−17.8 ± 0.1 kcal/mol and −22.7 ± 0.1 kcal/mol for SARS-CoV-2 and SARS-CoV, respectively). Five groups of mutations draw our attention at the RBD–ACE2 binding interface, among them, the mutation –PPA469-471/GVEG482-485 has the most important and favorable impact on SARS-CoV-2 binding to the ACE2 receptor. These results, highlighting the molecular differences in the binding between the two viruses, contribute to the common knowledge about the new corona virus and to the development of appropriate antiviral treatments, addressing the necessity of ongoing pandemics.

Keywords SARS-CoV · SARS-CoV-2 · RBD-ACE2 · Molecular modeling

Hien T. T. Lai, Ly H. Nguyen, and Anh D. Phan contributed equally to this work.

1 Key Laboratory for Multiscale Simulation of Complex Systems, VNU University of Science, Vietnam National University, 334 Nguyen Trai street, Hanoi 11416, Vietnam
2 Faculty of Materials Science and Engineering, Phenikaa Institute for Advanced Study, Phenikaa University, Hanoi 12116, Vietnam
3 Institute of Neuroscience and Medicine (INM-9)/Institute for Advanced Simulation (IAS-5), Forschungszentrum Jülich, Jülich 52428, Germany
4 Laboratoire de Biochimie Théorique, UPR 9080 CNRS, Université de Paris, 13 rue Pierre et Marie Curie, F-75005 Paris, France
5 Institut de Biologie Physico-Chimique-Fondation Edmond de Rothschild, SL Research University, 75005 Paris, France
6 CCFE, United Kingdom Atomic Energy Authority, OX14 3DB Abingdon, UK
Introduction

The COVID-19 disease that has rapidly spread from the Chinese Wuhan city to the rest of the world is caused by the 2019 novel coronavirus (2019-nCoV) named also the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. The sequencing of its genome revealed that it is closely related to other coronaviruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), which have killed hundreds of people in the last two decades [2, 3].

Coronaviruses are enveloped, positive sense, single-stranded RNA viruses that carry on their surface spike-like projections giving it a crown-like appearance under the electron microscope; hence the name coronavirus [4]. These spikes (S) enable the fusion between viral and host membranes and are essential for the beginning of the enveloped virus infection [5, 6]. They are composed of a large ectodomain, a trans-membrane anchor and a short intracellular tail (Fig. 1). The ectodomain consists of a receptor-binding subunit S1 and a membrane-fusion subunit S2 which are crucial for binding of the virus to the host cell surface and for entry of the viral genomes into the target cell, respectively [7–11]. The S1 subunit bears the Receptor Binding Domain (RBD) that recognizes and binds to the host protein receptor. The cellular entry receptor for SARS-CoV and SARS-CoV-2 is Angiotensin Converting Enzyme 2 (ACE2) [2, 12–16].

The viral RBD represents one of the main possible targets for the development of antiviral drugs, therefore, understanding the binding between the viral RBD and ACE2 is useful for rational drug design. The SARS-CoV and SARS-CoV-2 are closely related, nevertheless, significant differences were reported for their protein structures. Notably, the mutations in the SARS-CoV-2 RBD domain with respect to the SARS-CoV that can impact the binding affinity for the host receptor [14, 17, 18].

The aim of this study is to compare the structural and energetic differences in the binding of the RBDs of SARS-CoV-2 and SARS-CoV to the ACE2 receptor by Molecular Dynamics (MD) simulations and Molecular mechanics with generalized Born and surface area solvation (MM/GBSA) free energy calculations. Three different systems of ACE2 in complex with the SARS-CoV/SARS-CoV-2 RBDs were studied: (i) SARS-CoV RBD in complex with ACE2, Protein Data Bank (PDB) code: 2AJF [19] (ii) SARS-CoV-2 RBD in complex with ACE2, PDB code: 6M0J [20] (iii) a chimeric SARS-CoV-2 RBD in complex with ACE2, PDB code: 6VW1 [18].

The primary structures of the above systems were compared and five groups of mutations draw our attention. By means of MD simulations the most persistent interactions at the RBD-ACE2 interface were identified and consequently grouped into three binding hot-spots. Binding free energies for the RBD-ACE2 complexes were calculated by means of MM/GBSA method and then decomposed in order to calculate the contribution (i) of each RBD-ACE2 interaction persistent for at least 90% of the MD simulation time and (ii) of each mutation in the five mutation groups.

Our study contributes to better understanding of the binding characteristics between the old and the new coronavirus strains, assisting the process to provide a treatment for SARS-CoV-2 and help to control the pandemic.

Methods

The RBD - ACE2 complexes were obtained from the RCSB PDB database with IDs: 6M0J [20] for the new SARS-CoV-2 virus, 6VW1 [18] for its chimera, and 2AJF [19] for the SARS-CoV virus. For easy identification, these systems
were named 6VW1, 6M0J and 2AJF throughout the article, respectively. The 6VW1 and 2AJF systems contain two complexes of the ACE2 receptor (chains A and B) and the viral RBD domain (chains E and F). While the 6M0J contains only one complex of the ACE2 receptor (chain A) and the viral RBD domain (chain E). In our studies, we kept for each system only one complex of ACE2 (chain A) and the viral RBD (chain E) in order to better compare them to one another. Another reason we decided to continue only with chains A and E is that the complex of chains B and F is about 180° rotation symmetry of the complex of chains A and E. This is an artifact of protein crystallization, not actual arrangement of the complexes in real biological system.

There are some notable structural elements in these complexes that need special care when setting up the simulation systems such as the disulfide bonds between various pairs of cysteine residues; the N–linked glycosylations of various asparagine residues; and the Zn–Glu–His zinc–finger–like (ZF-like) motif (Supplementary Information file, Table S1). In addition, the experimental structures of ACE2 and RBD have some missing residues in their central parts (D615 for ACE2 and A522 for RBD). These residues were added using homology modeling method MODELLER [21–23].

Sequence alignment and the choice of mutations

The primary sequences of RBDs from 2AJF, 6VW1 and 6M0J were aligned by means of ClustalW web-server [24] using BLOSUM matrix [25] and then visually analyzed in order to find naturally occurring mutations between the SARS-CoV and SARS-CoV-2 using criteria described in details in the Results Section, Sequence and structural analyses.

Molecular dynamics (MD) simulation

The initial 2AJF, 6VW1 and 6M0J systems, composed of the chain A (human ACE2) and the chain E (viral RBD), were prepared for MD simulations using CHARMM-GUI web-server [26], and then modified manually to properly describe some particular structural elements (Supplementary Information file, Table S1). The MD simulations [27] were performed by GROMACS/2018.6 software package [28]. Proteins and ions were described by Charmm-36 force-field [29] and glycans by GLYCAM06 force-field [30]. The TIP3P [31] model was used for water molecules. The three systems were solvated, sodium and chloride ions were added to the system to neutralize the total charges and to set physiological electrolyte concentration of solution at 150 mM NaCl. The simulation box size was chosen so that the proteins in the neighbor periodic box are at least 3 nm apart from each other. Since the electrostatic screening length at 150 mM NaCl concentration is about 7 Å, this 3 nm distance is more than enough to eliminate the finite size effect due to the long-range electrostatic interactions among proteins in neighboring simulation boxes. In addition, the box size remains small enough that we can have results from MD simulation in a reasonable time regarding our current computational resources. The total numbers of molecules, residues and atoms for the three simulated systems are listed in Supplementary Information file, Table S2.

The geometry of all three studied systems was optimized by steepest descent minimization performed for 5,000 steps with a maximum force constant value of 1000 kJ/mol/nm. After the geometrical optimization, the systems were equilibrated in NPT ensemble for 1 ns at a timestep of 2 fs. The temperature of 310 K and the pressure of 1 atm were maintained by the Berendsen thermostat and barostat [28]. The Particle Mesh Ewald (PME) method [32] was used to treat the long-range electrostatic interaction with a real space cutoff of 1.2 nm. The van der Waals interactions were also cut off at 1.2 nm, with the appropriate cutoff corrections added to pressure and energy. All hydrogen bonds were constrained by the LINCS method [33].

After the equilibration, 2 µs MD production run at a timestep of 2 fs was performed for statistics. MD simulation parameters were the same as in the NPT equilibration run but the thermostat was changed to the Nose-Hoover thermostat [34–36] and the barostat to the Parrinello-Rahman barostat [37, 38].

Analyses

The structural stability/flexibility was determined by calculating the Root Mean Square Deviation (RMSD) of the backbone and the Root Mean Square Fluctuations (RMSF) of the Cα atoms for each residue. The center of mass (COM) distances were calculated between the two RBD segments and their counterpart ACE2 residues L79–Y83. The two RDB segments are as follows: (i) residues T470–C480, which include VPF2AJF and PD2AJF mutation groups, and (ii) residues F486–Y489 that represent the SARS-CoV-2 blue binding pattern. These calculations were performed using GROMACS scripts [28].

The buried surface area (BSA) at the ACE2–RBD interface was calculated as follows, where the solvent accessible surface area (SASA) values were obtained by GROMACS scripts [28]:

\[
\text{BSA}_{\text{interface}} = (\text{SASA}_{\text{ACE2}} + \text{SASA}_{\text{RBD}}) - \text{SASA}_{\text{ACE2–RBD}}
\]  

(1)

Frequencies of the RBD interactions with the ACE2 receptor were calculated using in-house made TCL and AWK scripts (reported in the Supplementary Information file). The RBD residues found within 5 Å of any residue belonging to ACE2 were counted as interacting with each other. Only contacts between heavy atoms were taken into
account. The frequency of binding was calculated as the number of frames the two residues interact divided by the total number of frames (2001 frames). Residues interacting for at least 90% of the simulation time are presented in Table 1. The type of interactions (van der Waals, electrostatic, hydrophobic or π-cation interactions) was defined by visual inspection in VMD [39].

The hydrogen bonds: Possible Hbond pairs identified by the above-mentioned TCL and AWK scripts were then analyzed by the g_hbond tool in the Gromacs package [28] in order to define their persistence in time. The Hbonds were determined by geometric criteria, namely the distance between the donor and acceptor atoms was at most 3.5 Å, and the angle of the three atoms making up the hydrogen bond was less than 30°. The Hbond persistence in time was calculated as the number of frames the two residues interact through the Hbond divided by the total number of frames (2001 frames) (Table 1 and Supplementary Information file, Table S3).

The binding free energy was calculated for the three RBD-ACE2 complexes, 2AJF, 6M0J and 6VW1, in order to compare the binding affinity of viral RBD for the human ACE2 receptor.

The Molecular mechanics with generalized Born and surface area solvation (MM/GBSA) method was employed using the mmpbsa.py script (Eqs 2 & 3) [40, 41]. The resulting binding free energies were scaled down using the scaling factor of 2.45 as proposed for the MM/GBSA method by DasGupta et al. [42].

The binding free energies were calculated based on the MD trajectories of 2 μs, employing 2001 frames sequenced by a time interval of 1 ns (we checked that this is large

| ACE2-RBD interactions persistent for more than 90% of the 2 μs simulation time |
|---------------------------------|-------------------------------|-----------------|----------------|----------------|
| **ACE2** | **SARS-1** | **SARS-2** | **Hbond** | **Hydrophobic** | **π-cation** |
| Q24 | A475 | G476 | N487 | Y489 | F456 | Y473 | A475 | Y489 |
| T27 | | | | | | | | |
| F26 | Y489 | L455 | | | | | | |
| D30 | | | | | | | | |
| K31 | L455 | | | | | | | |
| H34 | Y40 | Q193 | Y453 | L455 | Q193 | Y442 | F456 | Y442 | Y489 |
| E35 | Q493 | Q493 (45%) | | | | | | |
| Y41 | T486 | Q488 | T500 | | | | | |
| Q42 | Y436 | Y484 | | | | | | |
| L79 | M82 | | | | | | | |
| Y83 | N487 | | | | | | | |
| N330 | T486 | Y489 | T500 | | | | | |
| G352 | T487 | | | | | | | |
| K355 | N501 | G488 (86%) | G502 (76%) | | | | | |
| C354 | G488 | G502 | T487 | | | | | |
| D355 | Y491 | Y491 | Y505 | | | | | |
| R357 | T486 | T500 | N501 | | | | | |

Systems: SARS-1 – SARS-CoV (2AJF); SARS-2 – SARS-CoV-2 (6M0J & 6VW1). Type of interactions: vDW – van der Waals, Hbond – hydrogen bond, hydrophobic – hydrophobic contacts/interactions, π-cation interactions. Only Hbonds with persistence of at least 40% of the simulation time are shown. More Hbonds with lower probability are shown in Table S3. Residues in the same line occupy the same position in the sequence alignment (see Fig. 2). Residues in red/green/blue colors belong to the red-K31, green-K353 and blue-M82 binding patterns, respectively. See also Fig. 5.
enough to assure that the energies are non-correlated). The correlation time for our systems was defined by plotting the auto-correlation function of the total energy from the MD simulation code (Supplementary Information file, Fig. S3). The solute dielectric constant was set to 1.0 and the solvent dielectric constant to 80.0. The salt concentration was kept the same as in the MD simulation, notably 0.15M.

In addition, per-residue and per-interaction (i.e., pairwise) binding free energies (Eq. 3) were calculated using the same method. The per-residue binding free energy was calculated for each residue in the five chosen groups of mutations, and it represents a sum of binding free energies for all interactions the single residue forms with the counterpart ACE2 residues and with its neighbor residues in the viral RBD. In contrast, per-interaction binding free energies were calculated for a single interaction between a chosen residue in RBD and its corresponding residue in ACE2.

\[
\Delta G_{\text{binding}} = G_{\text{complex}} - (G_{\text{ACE2}} + G_{\text{RBD}})
\]

\[
G = E_{vdW} + E_{\text{Elec}} + G_{\text{Polar}} + G_{\text{non-Polar}}
\]

In the equation Eq. 2, the total energy value of each part is a sum of van der Waals (\(E_{vdW}\)), Electrostatic (\(E_{\text{Elec}}\)), Polar (\(G_{\text{Polar}}\)) and non-Polar (\(G_{\text{non-Polar}}\)) energies of this part (Eq. 3). Here, \(vdW\) and electrostatic energies were calculated in vacuum, while the last two terms are the free energies of solvation. The \(G_{\text{Polar}}\) is the reduction of electrostatic energy when charges are transferred from vacuum into the solution. Since the electric field is reduced by an averaged factor of 8-10 in solution compared to vacuum, \(E_{\text{Elec}}\) and \(G_{\text{Polar}}\) nearly cancel each other. For the \(G_{\text{non-Polar}}\) term, the SASA model is used, where it is calculated as the solute–solvent surface area multiplied by a surface tension factor. This surface tension is semi-empirical and set by default to 0.0227 kJ/mol/Å². There is a constant \(E_{\text{bonded}}\) energy of bonded interaction, which cancels out when taking the free energy differences.

The Visual Molecular Dynamics (VMD) program [39] was used for visualization, spatial inspection, surface analyses and for making figures.

**Results**

**Sequence and structural analyses**

The three RBD structures used in our study in complex with ACE2 are from SARS-CoV (PDB code: 2AJF [19]), and two SARS-CoV-2 viruses (PDB codes: 6VW1 [18] and 6M0J [20]). Residues numbering throughout the manuscript corresponds to SARS-CoV-2 RBD. When SARS-CoV RBD or ACE2 numbering is used, their names are added in the subscript, 2AJF for SARS-CoV RBD and ACE2 for the receptor, respectively. The sequences of the human ACE2 receptor are clearly identical in all three studied complexes, there are some small variations in glycosylation (Supplementary Information file, Table S1).

Unlike the human ACE2 receptor, the sequences of coronavirus RBDs differ to varying degrees (Fig. 2). The RBD sequence identity between the SARS-CoV-2

Fig. 2 Sequence alignment of viral RBDs structures of SARS-CoV-2 (6M0J), its chimera (6VW1) and SARS-CoV (2AJF). The orange box delineates the Receptor Binding Motif (RBM) in all three systems. Within RBM the chimera 6VW1 residues are the same as in 6M0J sequence, while outside RBM they correspond to 2AJF. Five groups of mutations that draw our interest at the RBD-ACE2 interface are highlighted in yellow. RBD-ACE2 interface residues that interact with each other for at least 90% of the simulation time are shown in red, green and blue, corresponding to red-K31, green-K353 and blue-M82 binding patterns, respectively. The grayed-out residues are those missing in the PDB crystal structures.

* Springer
coronavirus (PDB ID: 6M0J) and its chimeric sequence (PDB ID: 6VW1) is 86%, while the sequence identities between SARS-CoV (2AJF) and the two SARS-CoV-2 proteins (6M0J and 6VW1) are 71% and 83%, respectively. Chimera is composed of the SARS-CoV RBD sequence but its Receptor Binding Motif (RBM) sequence (Fig. 2, orange box) is copied from SARS-CoV-2. The $C_\alpha$-RMSD between the three structures after the minimization and before the MD simulations are as follows: 2AJF in comparison to 6M0J has the RMSD value of 4.6 Å and in comparison to 6VW1 of 4.2 Å, while the SARS-CoV-2 and its chimera structures differ for 4.9 Å.

We included the chimeric structure in our study in order to understand whether RBM plays the major role causing the difference in ACE2-binding of SARS-CoV-2 or it is the entire RBD. If chimera behaves as SARS-CoV-2 then RBM plays a major role in causing the difference in ACE2-binding with respect to the old strain. If not then the remaining RBD sequence also plays a crucial role.

Since we were interested in major differences in binding between SARS-CoV and SARS-CoV-2, we considered amino acids in the RBM region that are the same in the two SARS-CoV-2 sequences but are not-conserved in SARS-CoV. Among these amino acids, we selected groups of mutations based on the following criteria:

The first group of mutations that draw our attention was:

- **PPA469-471/GVEG482-485**: Two consecutive prolines introduce a certain rigidity into the protein backbone, while the insertion of glycines and the substitutions of the two prolines can lead to higher flexibility of this segment. We hypothesize that GVEG sequence allows this segment to move closer to the ACE2 receptor with respect to the SARS-CoV and to enable the negatively charged E484 residue to form electrostatic interaction with the positively charged residue K31 of the human ACE2 receptor. We focused then on other SARS-CoV proline mutations found in the RBM sequence alignment and we formed groups of mutations, including one mutation preceding and/or succeeding the proline residues if they introduce an important physico-chemical change. Based on this criteria we ended up with other two groups of mutations including proline residues:

- **VPF458-460/EIY471-473**: This triplet of residues is placed near the interface with the ACE2 receptor, but only the last residue physically interacts with the receptor. The polar and charged glutamic acid instead of hydrophobic valine is favorable in this position since this position is solvent exposed. The rigid proline is exchanged with isoleucine. We hypothesize that this will introduce better flexibility of the protein backbone of this small segment in the new viral structure. Finally, the hydroxyl group of Y473 leads to the possibility for the Hbond interaction with the T27 in ACE2 receptor.

- **PD462-463/AG475-476**: The rigid and bulky, charged amino acids of SARS-CoV (P462 and D463, respectively) are mutated to the smaller and hydrophobic residues (A475 and G476) in the SARS-CoV-2. This change can cause higher flexibility of the loop facilitating that this loop moves closer to the ACE2 receptor and is more prone for binding. The mutation preceding the proline in this group is S461/Q474 (see Fig. 2). We did not include it in the group, since these are both polar residues, very similar in size and do not introduce an important physico-chemical change. Another mutation that draws our attention is mutation YL442-443/LF455-456 for a reason that bulky amino acids are changed for small ones in a reverse order. To this group we added then another SARS-CoV tyrosine mutation of Y484/Q498, for the same reason, bulky polar amino acid is exchanged for polar residue but smaller one:

- **YL442-443/LF455-456**: The first mutation leads to the loss of the aromatic ring and especially of the hydroxyl group of tyrosine, removing the possibility for hydrogen bond with the receptor counterpart residues K31 or E35. In addition, it introduces smaller amino acid in the position of bulkier one. The second mutation is reversed, it exchanges a small hydrophobic amino acid for a bulkier one.

- **Y484/Q498**: this mutation turns the T-stacking hydrophobic interaction between the two tyrosines at the SARS-CoV RBD-ACE2 interface into the electrostatic interaction of SARS-CoV-2 glutamine with the opposing Q42 residue in the ACE2 receptor.

In summary, based on these sequence analyses using the above-mentioned criteria we selected five groups of mutations that may cause the increased backbone flexibility in the RBM motif (when prolines are mutated into other residues) and that introduce physico-chemical changes. We hypothesize that higher backbone flexibility of the part of the SARS-CoV-2 RBM would allow it to adapt better to the receptor binding interface, increasing the number of contacts between the two proteins. The selected five mutation groups, which are located at the RBD-ACE2 binding interface or in its proximity, were studied by MD simulations and Binding free energy calculations. It was out of the scope of this paper to study all mutations found in the SARS-CoV-2 RBM sequences.

Structural stability between SARS-CoV-2 and SARS-CoV from MD simulations

Thermal-dynamical movements of the ACE2-RBD complexes in all three studied systems were investigated by
means of molecular dynamics (MD) simulation. The three RBD domains differ in length, therefore we included in the analyzes only the so-called core RBD region that encompasses residues from 335-CPFGE to VVLSFE-516 (see Fig. 2).

The human ACE2 protein shows similar behavior in all three systems and it is stable with RMSD variations of less than 4 Å with respect to its experimental X-ray structure (Supplementary Information file, Fig. S1). The SARS-CoV-2 RBDs are more stable than SARS-CoV RBD. They deviate from their minimized structures for about 1.5 Å while SARS-CoV RBD varies for about 3.5 Å (Fig. 4(a)). As a result of these RMSD analyses, in all subsequent equilibrium statistical analyses for the RBD, the first 100 ns of the MD trajectories will be dropped. We calculated as well RMSF for the viral RBDs (Fig. 4(b)). The SARS-CoV-2 RBD domains behave very similar to each other and are more stable, with less thermal fluctuations, than the SARS-CoV RBD. We describe the most notable differences of the RMSD and RMSF values of the three systems here below.

Based on our observations, the higher RMSD value for the 2AJF system is caused by: (i) less compact RBD structure with respect to SARS-CoV-2 due to the shorter central β-strands composing anti-parallel β-sheet core of RBD. Higher fluctuations of these parts of SARS-CoV RBD are visible also in the RMSF graph corresponding to the area around SARS-CoV residue positions 327 and 342 (these positions correspond to indices 340 and 355 in the graph, respectively) (Fig. 4(b)); (ii) the missing S-S bridge C3782AJF–C5112AJF; experimentally resolved 2AJF sequence is shorter than the native one meaning that the C5112AJF was not resolved in the structure. The corresponding S–S bridge in SARS-CoV-2 (C391–C525) connects the C-terminal with the core body of RBD rendering it more stable. Since this interaction is missing in SARS-CoV structure that we used in our MD simulations, its RBD residues 367-387 fluctuate more than in the new viral strain (Fig. 4(b)), indices 380-400 in the graph); (iii) the lower RBM stability in SARS-CoV than in SARS-CoV-2 (Supplementary Information file, Fig. S2). We suggest that this is due to the proline residues present in the RBM section N457–Y475 (Figs. 2 and 3, mutation groups VPF458-4602AJF, PD462-4632AJF and –PPA469-4712AJF). Prolines render this section of 2AJF more rigid, i.e. less prone to adopt different conformations, therefore, it adapts less well to the binding surface of the ACE2 receptor forming with it less stabilizing interactions (Table 1, and the next subsection) than the RBM of SARS-CoV-2 where these prolines are mutated to other residues (Figs. 2 and 3, and subsection Mutations at the RBD-ACE2 interface). Consequently, this part in 2AJF has higher thermal fluctuations for the residues in the VPF458-460/EIY471-473 and –PPA469-471/GVEG482-485 mutation groups (Fig. 4(b), 2nd and 4th yellow bars). Instead, the thermal fluctuations of residues in the PD462-463/AG475-476 mutation group have similar values in 2AJF and 6VW1, which are higher than in 6M0J (Fig. 4(b), 3rd yellow bar). Furthermore, we observed that this RBM part in 2AJF detaches from the ACE2 receptor for about 600 ns (from 400 ns to 1000 ns) contributing to the higher RMSD values of SARS-CoV with respect to SARS-CoV-2 (subsection Mutations at the RBD-ACE2 interface and Supplementary Information file, Fig. S2).

Finally, the thermal fluctuations of the 2AJF residues in the first mutation group YL442-443/LF455-456 are higher in comparison to the new viral strains, while the residues in the last mutation group Y484/Q498 show very similar fluctuation values (Fig. 4(b), 1st and 5th yellow bars). The impact of these mutations on stability of binding interactions is discussed in subsection Mutations at the RBD-ACE2 interface.

The RMSF graph shows as well an increase of the RMSF values for 6VW1 around residues 440-460 (Fig. 4(b)). The 6VW1 region including this sequence is composed of a long loop, residues A443-Y451. This loop is located just before RBM and does not have direct and stable interactions with ACE2 (its sequence equals to the 2AJF sequence). In the beginning of the MD simulations this loop has the hairpin-like conformation in all three studied systems and is stabilized through five backbone Hbond interactions: D442-O–N448-NH, T444-O–T446-NH, T444-O–G447-NH, T444-NH–F497-O and N448-O–F497-NH. After the first 80 ns of the 6VW1 MD simulations the hairpin-like conformation of this loop changes to a more extended one due to the progressive loss of the Hbonds keeping together the two hairpin sides. In contrast, in the other two systems (2AJF and 6M0J) the Hbonds persist in time and the loop remains in its initial hairpin-like conformation during the full length of the MD simulations. We investigated what could be the possible effect of these changes on 6VW1 RBD. One possible effect we thought about was that there is a well-conserved Y449 located at the C-terminus side of this loop that forms very stable interaction with ACE2 in the 2AJF system, but not in the chimera nor in the 6M0J system. If the loss of interactions between Y449 and ACE2 was a consequence of the changed loop conformation in chimera, then this interaction should be preserved in the 6M0J system since its loop remains stable in the same conformation as in the 2AJF system. But in 6M0J this interaction is not stable either. Different loop conformation in 6VW1 also did not importantly impact the whole RBD, since the conformational change happens at around 80 ns, while the RBD RMSD is very stable throughout MD simulation. We carefully visually inspected the possible effects on 6VW1 RBD due to the loop conformation alteration but we could not identify any well visible effect despite higher local flexibility of this loop.
The interaction patterns between RBD and ACE2

Analyses were done to define the type of interactions which maintain the RBD-ACE2 complex and their persistence in simulation time was calculated (Table 1 and Supplementary Information file, Table S3). Only the interactions found for at least 90% of the MD simulation time at the RBD-ACE2 distance of less than or equal to 5 Å were taken into account. From Table 1, it is clear that at this criteria, the new coronavirus RBDs form about twice as much interactions with the ACE2 receptor as the SARS-CoV RBD. Hbond analyses were then done more in detail using standard Hbond criteria for the distance and angle values. We found that SARS-CoV-2 has higher probability to form Hbonds. Nevertheless, the fluctuations of the residues present in the five mutation groups. The residue indices of 2AJF were shifted and aligned according to the alignment table shown in Fig. 2, so that the corresponding amino acids of the three viruses are superimposed. Residue indices correspond to SARS-CoV-2 numbering, to obtain the SARS-CoV residue numbers subtract 13.

Fig. 4 Structural stability of viral SARS-CoV-2 RBDs throughout 2 μs of MD simulations. (a) The root-mean-square deviation (RMSD) was calculated for the backbone. Both systems of SARS-CoV-2 are represented in green and cyan curves, and SARS-CoV system is shown in red curve. (b) The root-mean-square fluctuations (RMSF) were calculated for Cα atoms. The yellow vertical lines highlight the fluctuations of the residues present in the five mutation groups.
two Hbonds in each strain have their lifetime longer than 70% of the simulation time, while others show much lower persistence (Supplementary Information file, Table S3). The bigger number of interactions in SARS-CoV-2 RBD could be associated with its higher binding affinity.

Two binding patterns were identified that are common to both, SARS-CoV and SARS-CoV-2 viruses, while one binding hot-spot was found to be inherent to SARS-CoV-2.

The first pattern, which we named red-K31 (Table 1 and Fig. 5, red balls), includes residues at the very beginning of the ACE2 N-terminus, notably Q24\textsubscript{ACE2}, E35\textsubscript{ACE2}, K31\textsubscript{ACE2} and H34\textsubscript{ACE2}. These four residues interact with RBDs in all three systems, while other residues in this pattern interact constantly only with SARS-CoV-2 RBDs. K31\textsubscript{ACE2} forms π-cation interactions with Y442\textsubscript{2AJF} and with Y489 in SARS-CoV-2. In the latter it interacts also with L455, Q493 and F456. H34\textsubscript{ACE2} forms vdW interactions with Y440\textsubscript{2AJF} and with L455 and Q493 in the new strain.

The second pattern, which we named green-K353 (Table 1 and Fig. 5, green balls), consists of ACE2 residues Y41\textsubscript{ACE2}, N330\textsubscript{ACE2}, K353\textsubscript{ACE2}, G354\textsubscript{ACE2}, D355\textsubscript{ACE2} and R357\textsubscript{ACE2}. They bind with RBD counterpart residues, forming vDW. Hbond, hydrophobic and also π-cation interactions (Table 1). The latter is formed between K353\textsubscript{ACE2} and Y491\textsubscript{2AJF} or Y505 in the new virus strain, respectively.

While these two patterns are found in old and new virus strains alike, the third interaction patch, named blue-M82, (Table 1 and Fig. 5(a), blue balls) was observed almost exclusively in the SARS-CoV-2. It is formed between the ACE2 residues L79\textsubscript{ACE2}, M82\textsubscript{ACE2} and Y83\textsubscript{ACE2} and their correlative residues in RBD. The first two residues form hydrophobic interactions with the F486, while the last one makes vDW interactions with N487 and Y489 in addition to the parallel-displaced π-stacking interaction with F486. In the 2AJF system, only one interaction appears in this pattern (Y475\textsubscript{2AJF}– Y83\textsubscript{ACE2}) that persists for 70% of the simulation time not reaching our criteria of persistence of at least 90%. We observed indeed, as already said above, that 2AJF RBD detaches from the ACE2 during the MD simulation (between around 400 ns and 1000 ns, Supplementary Information file, Fig. S2) and we see here that it detaches exactly at the location of the third binding pattern. We discuss this fact more in detail in the next subsection.

---

**Fig. 5** Residues composing the binding patterns at the ACE2-RBD interface in (a) SARS-2 (SARS-CoV-2; 6M0J & 6VW1) and (b) SARS-1 (SARS-CoV; 2AJF) systems. Red and green balls represent the red-K31 and the green-K353 binding patterns that are common to both SARS-1 and SARS-2 coronavirus. The blue balls depict the blue-M82 binding pattern that is constantly formed in our MD simulations only in SARS-2. Green lines represent Hydrogen bonds persistent for at least 40% of the MD simulation time. For more details about the interaction pairs and types of interaction see Table 1.
Mutations at the RBD-ACE2 interface

We identified and focused our analyses on five groups of mutations: YL442-443/LF455-456, VPF458-460/EIY471-473, PD462-463/AG475-476, –PPA469-471/GVEG482-485, Y484/Q498 (Fig. 2). In the first mutation group YL442-443/LF455-456, Y4422AJF, L455 and F456 interact steadily with the ACE2 receptor (Table 1). The number of vdW and hydrophobic interactions in SARS-CoV-2 compensates well for the loss of π-cation interaction present in SARS-CoV between Y4422AJF and K31ACE2. We have not observed stable Hbonds between Y4422AJF and K31ACE2 or E35ACE2.

The constant interactions were observed between ACE2 and the SARS-CoV-2 residues in the second, the third and the fourth set of mutations, while they are absent in SARS-CoV (Table 1).

These three sets of mutations are located in the RBM section, residues T470 – Y489. We calculated the center of mass (COM) distance of the two segments of this RBM part with respect to its ACE2 counterpart (Fig. 6). The first segment includes residues T470 – C480, and VPF458-460/EIY471-473, PD462-463/AG475-476 mutation groups (Fig. 2). In the new viral strains the center of mass of this segment shows throughout the MD simulation small and steady fluctuations around the average distance of 10.7 Å from ACE2. In contrast, the same segment in SARS-CoV fluctuates more and at around the average distance value of 12.1 Å (Fig. 6(a)).

The second segment, residues G482 – Y489, for which we calculated the COM distances includes –PPA469-471/GVEG482-485 mutation group (Fig. 2). In SARS-CoV-2 this segment fluctuates steadily around the average distance value of 6.1 Å while it fluctuates much more in the old strain and around higher average distance value of 9.6 Å (Fig. 6(b)).

We observe that the three mutation groups including proline residues in the RBM section T470 – Y489, cause the difference in binding between the two viruses. As we and others [18] suggested, the substitution of rigid prolines for other residues makes the backbone more flexible, i.e. more prone to adopt different conformations and consequently to adapt better to the ACE2 binding surface. In turn, more residues in this section can form stable interactions with ACE2 rendering it more stable in time what reflects through more stable RMSD, RMSF and COM values with respect to the SARS-CoV strain.

Indeed, mutations in the first segment lead to the regular interactions between Y473, A475 and G476 residues and ACE2 (Table 1), while the interactions of the same SARS-CoV segment with ACE2 are less constant (their persistence in time is less than 90%).

The –PPA469-471/GVEG482-485 mutation in the second segment has even stronger impact on SARS-CoV-2 binding to ACE2. While residues in this group do not directly interact with ACE2, residues following them — F486, N487 and Y489 — are brought closer to the ACE2 receptor and new interactions, very stable in time are established. Very interestingly, residues F486, N487 and Y489, form the third binding pattern, unique to the SARS-CoV-2, that we named blue-M82 (subsection The interaction patterns between RBD and ACE2, Table 1, Fig. 5, blue color).

As already mentioned above, the presence of a group of prolines that are located very close to one another in this SARS-CoV section of RBM (residues Y440- E502) leads to less flexible backbone and consequently to less conformational freedom. As seen from our results, this leads to less persistent contacts between this SARS-CoV RBM section and ACE2 provoking a well visible detachment of this part of RBD from the receptor for about 600 ns during the MD simulation (from 400 ns to 1000 ns) (Fig. 6 and Supplementary Information file, Fig. S2(b)).

Finally, in the fifth mutation group, Y484/Q498, both residues constantly interact with the ACE2 receptor (Table 1).

Based on the results from these qualitative analyses, we extended our study with binding free energy calculations: (i) to evaluate the binding affinity between the two SARS strains; (ii) to calculate binding free energy contributions of RBD-ACE2 interactions defined in Table 1 and (iii) to assess the impact of mutations on RBD-ACE2 binding.

Fig. 6 The center of mass (COM) distance between SARS-CoV-2 T470–C480 (N457–C467 in SARS-CoV) loop (a) or G482–Y489 loop (P469–Y475 in SARS-CoV) (b) and their counterpart ACE2 residues L79–Y83 belonging to the blue pattern during the 2 μs simulation time. The green and blue lines are for 6VW1 and 6MOJ systems, respectively, and the red line is for the 2AJF system.
Binding free energy calculations

Binding free energies were calculated for the three RBD-ACE2 complexes using the Molecular mechanics with generalized Born and surface area solvation (MM/GBSA) method [40] (see Methods, equations 2 and 3). We performed a number of tests employing Molecular mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) and Molecular mechanics/generalized Born Surface Area (MM/GBSA) methods, applying different solute dielectric constants (1.0, 2.0 and 4.0) and salt concentrations of 0.0 M and 0.15 M (results not shown). We found out that for our systems the MM/GBSA method, with solute dielectric constant of 1.0 results in binding free energies that are the most compatible with the experiments [18, 43, 44]. Salt concentrations did not have important impact on the resulting binding free energies, therefore 0.15 M was used as in the MD simulation. It is well known that MM/PBSA and MM/GBSA usually overestimate the absolute binding free energy, therefore the resulting binding free energies were scaled down using the scaling factor of 2.45 as proposed for the MM/GBSA method by DasGupta et al. [42]. So obtained binding free energy results were used to estimate the qualitative differences between the two COVID viruses, not the absolute values of the binding free energies.

Based on our calculations (Supplementary Information file, Table S4) the electrostatic, vdW and hydrophobic interactions are in favor of SARS-CoV-2. The MM/GBSA calculated and scaled down binding free energy for SARS-CoV-2 is of $-13.50 \pm 0.09$ kcal/mol. The binding free energy was similar for the chimeric structure, but a little less favorable for the SARS-CoV complex ($-12.56 \pm 0.07$ kcal/mol, $-10.96 \pm 0.13$ kcal/mol, respectively). Our result that SARS-CoV-2 binds for about 2.5 kcal/mol more strongly to the ACE2 receptor than SARS-CoV is much more compatible with the experiments [18, 43, 44] than the binding affinity differences, as high as $20 - 30$ kcal/mol, reported previously by other similar computational studies [45–47].

We suppose that the major differences between the two viruses lie in the specific types of interactions among the individual amino acids which we analyze in detail here below, with particular focus on mutations of our interest.

Pairwise decomposition of binding free energy

We decomposed SARS-CoV and SARS-CoV-2 binding free energies into a per-interaction (i.e. per-wise) binding free energy in order to identify interactions reported in Table 1 that contribute the most to the virus-receptor binding. The binding free energies reported here were calculated for a single interaction between the residue in RBD and the corresponding residue in ACE2 (Table 2).

| Table 2 Binding free energy (in kcal/mol) per-interaction for all RBD-ACE2 interactions persisting for at least 90% of the simulation time |
|---|
| ACE2 | SARS-1 | SARS-2 | SARS-2 | SARS-3 |
| | AAA | 2AF | | |
| Q24 | $-0.9$ | $-0.9$ | $-0.9$ | $-0.9$ |
| T37 | $-0.9$ | $-0.9$ | $-0.9$ | $-0.9$ |
| F55 | $-0.9$ | $-0.9$ | $-0.9$ | $-0.9$ |
| D60 | $-0.9$ | $-0.9$ | $-0.9$ | $-0.9$ |
| K31 | $-0.9$ | $-0.9$ | $-0.9$ | $-0.9$ |
| H34 | $-0.9$ | $-0.9$ | $-0.9$ | $-0.9$ |
| Y41 | $-0.9$ | $-0.9$ | $-0.9$ | $-0.9$ |
| M52 | $-0.9$ | $-0.9$ | $-0.9$ | $-0.9$ |

ACE2 residues highlighted in red/green/blue background colors and the SARS-1/2 residues listed in the same lines belong to the red-K31, green-K353 and blue-M82 binding patterns, respectively. The total binding free energy and the standard errors of the mean are reported for each residue and each pattern; values ”$> -0.9$" were excluded; SARS-1, SARS-CoV; SARS-2, SARS-CoV-2.

In the red-K31 pattern, SARS-CoV has two stable interactions, K31ACE2–Y4422AF and H34ACE2–Y4402AF, but only the first one has a strong binding free energy contribution. The $\pi$-cation interaction was expected between K31ACE2–Y4422AF, though the binding free energy value is not as high as in other similar interactions. A possible explanation could be non-optimal spatial position of the two residues for the formation of a strong $\pi$-cation interaction. SARS-CoV-2 system instead has five residues that strongly interact with K31ACE2 and H34ACE2. In addition, other stable, strong interactions are formed between SARS-CoV-2 RBM and ACE2 receptor in this pattern, notably with Q24ACE2, T27ACE2, F28ACE2, D30ACE2 and E35ACE2 (Table 2).
The total binding free energy contribution of the red-K31 pattern is much bigger in SARS-CoV-2 (−23.45 ± 0.24 kcal/mol) than in SARS-CoV (−1.78 ± 0.02 kcal/mol) (Table 2), giving to SARS-CoV-2 an important advantage for binding to the human receptor, with respect to the old virus.

In the green-K353 pattern, the old and the new virus have very similar number of stable interactions, as well as the values of binding energies between these interactions. This may indicate the great importance of this binding pattern for the SARS virus entry into the human host regardless of the strain. SARS-CoV has few more constant interactions in this pattern than SARS-CoV-2 (Table 1). The strongest interactions within this pattern are π-stacking between Y41ACE2–Y4842AJF, Hbond between K353ACE2–T4872AJF/N501, π-cation interactions between K353ACE2–Y4912AJF/Y505 and Hbond between D355ACE2–T4862AJF/T500. The green-K31 pattern total binding free energy is a little in favor of SARS-CoV (−22.74 ± 0.13 kcal/mol) in comparison to the new virus (−17.77 ± 0.23 kcal/mol) (Table 2).

As already said above, these two patterns were found in both, old and new SARS viruses. The third binding pattern, blue-M82, with the interactions persistent for more than 90% of the simulation time, was instead observed only in SARS-CoV-2. This pattern gives an important additional contribution of −9.08 ± 0.06 kcal/mol (Table 2) to the total binding free energy between SARS-CoV-2 and its host receptor. Interactions within this pattern are mostly hydrophobic and an Hbond with 81% of persistence in simulation time is formed between Y83ACE2 and N487.

The total pairwise binding free energy contribution of the three binding patterns is of −50.30 ± 0.53 kcal/mol in SARS-CoV-2 and of −24.52 ± 0.15 kcal/mol in SARS-CoV (Table 2).

**Effect of mutations on RBD-ACE2 binding free energy**

The binding free energies for SARS-CoV-2 and SARS-CoV were decomposed into a per-residue based binding free energy for the five groups of mutations to evaluate the effect that single RBM mutation has on viral binding (Table 3). They were calculated as a sum of binding free energies for all interactions a single residue in this group forms with counterpart ACE2 residues and with its neighboring residues in the viral RBM.

In the first group, YL442-443/LF455-456, the exchange of bulky Y4422AJF side chain with the polar-OH group, for smaller and hydrophobic L455 does not have an important effect on binding free energy since the original hydrophobic interaction is preserved. In contrast, exchanging small L4432AJF for bigger F456 induces a ΔG binding increase for about 1 kcal/mol (Table 3). Indeed, L4432AJF interacts few with ACE2. But, F456 – due to its bulkier side chain – becomes stably sandwiched between T27ACE2-CH3 group and the K31ACE2 side chain -CH2- groups forming hydrophobic interactions.

The second, the third and the fourth groups of studied mutations do not form strong interactions with the ACE2 receptor as it can be seen from their negligible ΔG binding, except P462/A475. Both residues form hydrophobic interactions with -CH2-groups of Q24ACE2 and T27ACE2: Residues Y473, A475 and G476 form weak hydrophobic and vdW interactions with ACE2 and exhibit similar ΔG binding as the corresponding residues in SARS-CoV, but they constantly interact with ACE2 for more than 90% of the simulation time, while the old strain residues do not.

The fourth group of mutations, –PPA469-471/GVEG482-485, makes the backbone of this segment in SARS-CoV-2 more flexible, since rigid proline residues were exchanged with small and flexible glycines. As already suggested

| Mutations | SARS-1 | SARS-2 |
|-----------|--------|--------|
|            | RESs   | 2AJF   | 6VW1 | 6MoJ | RESs   |
| YL/LF      | Y442  | −1.94 ± 0.03 | −1.84 ± 0.01 | −2.05 ± 0.01 | L455 |
|            | L443  | −0.88 ± 0.01 | −1.88 ± 0.01 | −2.04 ± 0.01 | F456 |
| VPF/ETY    | V458  | 0.02 ± 0.00 | 0.11 ± 0.00 | 0.11 ± 0.00 | E471 |
|            | P459  | −0.04 ± 0.00 | −0.05 ± 0.00 | −0.05 ± 0.00 | I472 |
|            | F460  | −0.19 ± 0.00 | −0.08 ± 0.00 | −0.11 ± 0.00 | Y473 |
| PD/AG      | P462  | −1.59 ± 0.02 | −1.17 ± 0.02 | −1.20 ± 0.02 | A475 |
|            | D463  | −0.03 ± 0.04 | −0.43 ± 0.01 | −0.53 ± 0.01 | G476 |
|            | P469  | 0.02 ± 0.00 | 0.01 ± 0.00 | 0.02 ± 0.00 | V483 |
|            | P470  | −0.04 ± 0.01 | 0.70 ± 0.02 | 0.25 ± 0.03 | E484 |
|            | A471  | 0.03 ± 0.00 | 0.08 ± 0.00 | 0.10 ± 0.00 | G485 |
| Blue-M82   | L472  | −0.52 ± 0.02 | −3.44 ± 0.02 | −3.53 ± 0.02 | F486 |
|            | N473  | −0.18 ± 0.02 | −1.65 ± 0.02 | −1.56 ± 0.02 | N487 |
|            | Y475  | −2.04 ± 0.04 | −1.13 ± 0.02 | −1.17 ± 0.01 | Y489 |
|            | Y484  | −3.04 ± 0.04 | −1.59 ± 0.02 | −1.25 ± 0.03 | Q498 |

The five mutation groups are highlighted in yellow; errors represent standard errors of the mean; SARS-1, SARS-CoV; SARS-2, SARS-CoV-2.
above, due to the higher flexibility this segment comes closer to ACE2 and remains in its vicinity throughout the MD simulation time (Fig. 6(b)) enabling residues F486, N487 and Y489, which follow immediately the GVEG motif, to constitute the blue-M82 binding pattern with strong binding affinity for the ACE2 receptor (Table 3). In contrast, the same 2AJF segment fluctuates much more and remains more distant from ACE2 during almost all MD simulation time (Fig. 6(b)). Among the three residues, F486 and N487 have bigger contribution to the $\Delta G_{binding}$ than the same residues in SARS-CoV with the values of $-3.53 \pm 0.02 \text{kcal/mol}$ and $-1.56 \pm 0.02 \text{kcal/mol}$, respectively. They form hydrophobic, $\pi$-stacking and vdW interactions with L79$_{\text{ACE2}}$, M82$_{\text{ACE2}}$ and Y83$_{\text{ACE2}}$. The $\Delta G_{binding}$ of the corresponding residues in SARS-CoV is negligible, pointing to the importance of these residues for SARS-CoV-2 binding. Indeed, F486 that corresponds to L472$_{2AF}$, with its bulkier side chain fits like a tenon in mortise composed of L79$_{\text{ACE2}}$, M82$_{\text{ACE2}}$ and Y83$_{\text{ACE2}}$. The third residue in this group is Y489 ($-1.17 \pm 0.01 \text{kcal/mol}$) and its corresponding residue in SARS-CoV is Y475$_{2AF}$, which has more favorable binding affinity ($-2.04 \pm 0.04 \text{kcal/mol}$). However, during our MD simulations it has lower frequency of interactions with the receptor than Y489 (70.1% vs 97.8%, respectively). In addition, the total contribution of binding affinity of these three SARS-CoV-2 residues in the blue-M82 pattern is greater than in SARS-CoV ($-6.26 \pm 0.05 \text{kcal/mol vs} -2.74 \pm 0.08 \text{kcal/mol}$, respectively; Table 3) adding an important binding spot in favor of the new virus strains.

In the fifth group, the mutation Y484/Q498 is less favorable for binding ($-3.04 \pm 0.04 \text{kcal/mol vs} -1.25 \pm 0.03 \text{kcal/mol}$, respectively). Indeed, Y484$_{2AF}$ forms parallel $\pi$-stacking interactions with Y41$_{\text{ACE2}}$ and intermittent Hbond with Q42$_{\text{ACE2}}$, while Q498 interacts only through weaker vdW interactions with Y41$_{\text{ACE2}}$.

Our results are in line with those reported by Spinello et al. [45]. We all found by means of MM/GBSA per-residue decomposition the favorable ACE2 binding free energy for same SARS-CoV-2 residues that we report in Table 3. And we all found that P462$_{2AF}$ has favorable binding for about 0.4 kcal/mol with respect to its counterpart SARS-CoV-2 residue A475. However, P462 does not interact constantly with ACE2 receptor while A475 it does. In contrast, they report about much stronger binding free energy for Q498 while we observed more favorable binding free energy for SARS-CoV residue Y484$_{2AF}$.

Discussion

Within a short time, a novel SARS-CoV-2 virus spread around the Earth, affecting health care, social and economic life in more than 250 countries. It immediately caught a great scientific interest, and different studies focused on binding of SARS-CoV and SARS-CoV-2 to the human ACE2 receptor, found to be a major entry for the novel virus into humans [13, 14, 18].

We have run MD simulation of 2 $\mu$s for the three complexes: SARS-CoV (2AJF)–ACE2, SARS-CoV-2 (6MU)–ACE2 and for the chimeric SARS-CoV-2 (6VW1)–ACE2 in order to compare binding between the old and the new coronavirus. We studied as well different groups of mutations existent at the RBD-ACE2 interface.

By means of the MM/GBSA method [40, 41] we estimated about 2.5 kcal/mol stronger binding affinity of SARS-CoV-2 with respect to the old strain. Our results are thus compatible with the very small experimental binding free energy difference (calculated from the experimentally reported Kd values [18, 43, 44]) of 0.8 – 1.4 kcal/mol in favor of the SARS-CoV-2. On the contrary, previous computational studies based on MM/PBSA– or MM/GBSA–techniques estimated that the binding of the new virus would be as much as 20 – 30 kcal/mol stronger with respect to the old one [45–47], incompatibly with experiments.

Regarding the stability, we observed the most notable difference in the RBM motif, which is much more stable in SARS-CoV-2 than in SARS-CoV. We furthermore observed that the long loop connecting $\beta5$ and $\beta6$ in SARS-CoV RBD (P459$_{2AF}$–Y475$_{2AF}$, corresponding to $\beta7$ and $\beta8$ in SARS-CoV-2), which interacts with the N-terminal part of ACE2, detaches from the receptor for about 600 ns (from 400 ns to 1000 ns). The loop then approaches again back to ACE2. Intermittent detachment of this SARS-CoV loop from the ACE2 receptor was reported also by Pavlova et al. [48].

According to our observations, the partial detachment in SARS-CoV is caused because of the rather rigid RBM segment N457 – 475$_{2AF}$ that includes four proline residues while the corresponding SARS-CoV-2 segment T470 — Y489 has only one. It is known that mutations may have not only direct but also indirect effects on binding. In our case the three mutation groups in this segment, VPF458-460/EIY471-473, PD462-463/AG475-476 and –PPA469-471/GVEG482-485 have indirect impact on SARS-CoV-2 binding through alteration of this segment conformation. The non-proline residues allow for better flexibility of this SARS-CoV-2 RBM section, leading to more conformational freedom thus this segment can adapt better to the ACE2 binding interface. While VPF458-460$_{2AF}$ and PD462-463$_{2AF}$ scarcely interact with ACE2, the corresponding SARS-CoV-2 residues Y473, A475 and G476 form constant interactions with ACE2. Even stronger indirect effect on binding has –PPA469-471/GVEG482-485 mutation.

As already suggested in Shang et al. [18], the GVEG482-485 sequence enables $\beta7$–$\beta8$ loop in SARS-CoV-2 RBD to move closer and to adapt better to the surface of the ACE2
receptor thus allowing to the surrounding residues to form more stable interactions. Notably, residues that follow the GVEG482-485 motif strongly and persistently interact with the blue-M82 binding pattern (five interactions, stable for 99% of the simulation time in SARS-CoV-2 vs one interaction persistent for 70% of the simulation time in SARS-CoV). Our calculations show that the interactions within the blue-M82 hot-spot (residues L79\_ACE2, M82\_ACE2 and Y83\_ACE2) contribute to the Δ\(G_{\text{binding}}\) in SARS-CoV-2 of −9.08 ± 0.06 kcal/mol.

In addition to the blue-M82 hot-spot, the red-K31 binding pattern contributes strongly to the Δ\(G_{\text{binding}}\) in SARS-CoV-2 with respect to SARS-CoV strain. This pattern, observed in SARS-CoV and SARS-CoV-2 alike, includes ACE2 residues Q24, T27, F28, D30, K31, H34, and E35. We found that SARS-CoV-2 has eight persistent interactions within this patch, while SARS-CoV has only two. This difference is partially a consequence of the detachment in the SARS-CoV that we described above. Therefore, there is a notable difference in the contribution of the red-K31 binding pattern to the Δ\(G_{\text{binding}}\) that is of −23.45 ± 0.24 kcal/mol for SARS-CoV-2 and of −1.78 ± 0.02 kcal/mol for SARS-CoV.

The third, green-K353 binding patch, comprises ACE2 residues Y41, Q42, N330, K353, G354, D355 and R357 and is placed at the opposite site of the blue-M82 patch. This binding pattern is equally stable in both strains, having the same number of interactions and similar total Δ\(G_{\text{binding}}\) contribution (−17.77 ± 0.23 kcal/mol for SARS-CoV-2 and −22.74 ± 0.13 kcal/mol for SARS-CoV).

Jafary et al. identified four hot-spot ACE2 residues (Q24–D38, Y41–Q42, M82–Y83 and N330–R357) playing important role in interactions of SARS-CoV and SARS-CoV-2 [46]. Our results are in line with theirs, but we grouped the hot-spot residues, according to their spatial arrangement into three groups, as described above. Our results are in line also with the findings of other groups that worked on identification and on comparison of critical interactions between the old and the new coronaviruses, though they do not necessarily group the ACE2 residues into the binding patterns.

Five groups of mutations (YL442-443/LF455-456, VPF458-460/EIY471-473, PD462-463/AG475-476, –PPA469-471/GVEG482-485 and Y484/Q498) were studied, in order to see how do they impact binding to ACE2. The mutation YL/LF, especially exchanging L443\_2AIF to F456 has a favorable impact on the binding affinity. L443\_2AIF, being small does not exhibit steady interactions with the ACE2 receptor, while bulkier F456 interacts with three counterpart residues T27\_ACE2, D30\_ACE2 and K31\_ACE2. Mutations in the second and the third groups, VPF458-460/EIY471-473 and PD462-463/AG475-476, do not exhibit any changes for the binding affinity between SARS RBD and ACE2.

The most important mutation is –PPA469-471/GVEG482-485, which increases the flexibility of SARS-CoV-2 RBD β7–β8 loop as already said above. Consequently, residues F486, N486, and Y489 come closer to the ACE2 receptor and constantly interact with the blue-M82 binding pattern. Within these residues the most favorable mutation for binding is L472/F486 (−0.52 ± 0.02 kcal/mol vs −3.53 ± 0.02 kcal/mol, respectively). The F486 residue is enveloped by the hydrophobic counterpart residues from the blue-M82 binding patch, L79\_ACE2, M82\_ACE2 and its bulky aromatic side chain is forming stable π-stacking interactions with Y83\_ACE2.

Our observations confirms scenario, which was suggested by Chen et al. [51].

And the last mutation Y484/Q498 is less favorable with −3.04 ± 0.04 kcal/mol in SARS-CoV vs −1.25 ± 0.03 kcal/mol in SARS-CoV-2. Indeed, Y484\_AIF is making favorable parallel π-stacking interaction with Y41\_ACE2 and intermittent Hbond with Q42\_ACE2. While the interactions of Q498 are limited to the weaker, vdW interactions with Y41\_ACE2. In our MD simulations Hbond with Y41\_ACE2 is formed very rarely. Experiments also demonstrated that at this position tyrosine is more adapted and exhibits favorable binding affinity with respect to the glutamine [52].

Our observations are in line with other computational studies focusing on advantages/disadvantages of mutations at the binding interface between the ACE2 receptor and the old and new coronaviruses [45, 48].

Finally, our results point out that chimera behaves very similar to SARS-CoV-2 indicating that RBM plays a major role in causing the difference in ACE2-binding between the old and the new strain and that the body of the RBD has little influence on RBM. There are rather mutations in RBM that impact binding affinity of the virus for the ACE2 receptor.

**Conclusion**

In light of many previous studies of RBD-ACE2 complexes and difference from that of SARS-CoV virus, we would like to stress that our work is a comprehensive extension of our preliminary results published in bioRxiv preprint (https://www.biorxiv.org/content/10.1101/2020.04.21.053009v1), when the experimental structure of SARS-CoV-2 RBD (PDB code: 6M0J) was just published (in April 2020).

From that time, several other works appeared investigating similar systems, but they focus mostly on the biochemical aspect of the interactions, specifically on the electrostatics and hydrogen bond formation or comparing the binding free energy contribution changes of a single mutation/interaction. Our manuscript differs from this line of thinking by studying the biophysical aspect of the five
main groups of mutations and of each binding pattern at the RBD-ACE2 interface. In our study we show that –PPA469-471/GVEG482-485 mutation triggers an important structural consequence: the substitution of prolines in SARS-CoV by glycines in SARS-CoV-2 makes the SARS-CoV-2 RBD backbone in this region more flexible, allowing it to adapt better to the receptor interface and resulting in formation of the additional persistent binding pattern (blue-M82). This result is in accordance with the experiments [18]. In addition, MD simulations and free energy calculations permit the evaluation and comparison of the impact this mutation has on the stability and on the strength of the interactions between SARS-CoV-2 and ACE2. We calculated that the pattern formed due to this mutation contributes importantly, about 9 kcal/mol to the binding free energy between SARS-CoV-2 RBD and ACE2.

Three binding patterns persistent in simulation time were found in SARS-CoV-2 (red-K31, green-K353 and blue-M82), but only two of them in SARS-CoV (red-K31, green-K353). The binding free energy difference that we observed between SARS-CoV-2 and SARS-CoV is of about 2.5 kcal/mol, a result compatible with the experiments.

Our results elucidate relevant information about the RBD-ACE2 binding interface and can assist in design of potential compounds/antibodies for inhibition of viral activities, contributing to provide viral therapy for COVID-19.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00894-022-05231-7.

**Acknowledgements** We thank Prof. Paolo Carloni and Linh G. Hoang for critical reading of the manuscript.

**Author contribution** Conceptualization, T.T.N., A.K. and D.N.; methodology, T.T.N. and D.N.; investigation, H.T.T.L., L.H.N. and A.D.P.; analyses, T.T.N., H.T.T.L. and A.K.; writing—original draft preparation, T.T.N., H.T.T.L. and A.K.; writing—review and editing, all authors; supervision, T.T.N., D.N and A.K.; project administration, T.T.N.; funding acquisition, T.T.N., H.T.T.L. and D.N. All authors have read and agreed to the published version of the manuscript.

**Funding** Open Access funding enabled and organized by Projekt DEAL. TTN received financial support from the Vietnam National University - Hanoi grant number QG.20.82. HTTL was funded by Vingroup Big Data Institute (VINBIGDATA), code VINIF.2020. Ths.21. DNM received support from the Euratom research and training programme 2019-2020 under grant no. 633053, and the RCUK programme under grant no. EP/T012250/1.

**Data availability** The MD trajectories generated and analyzed during the current study are available from the corresponding authors on reasonable request.

**Code availability** Not applicable

**Declarations**

**Ethics approval** Not applicable

**Conflicts of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Wang C, Horby PW, Hayden FG, Gao GF (2020) A novel coronavirus outbreak of global health concern. The Lancet 395(10223):470–473
2. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270–273
3. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-Y et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579(7798):265–269
4. Specter SC, Hodinka RL, Wiedbrauk DL, Young SA (2009) Clinical Virology Manual. American Society for Microbiology Press
5. Belouzard S, Millet JK, Licitra BN, Whittaker GR (2012) Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4(6):1011–1033
6. Sieczkarski SB, Whittaker GR (2002) Dissecting virus entry via endocytosis. J Gen Virol 83(7):1535–1545
7. Li F (2016) Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 3:237–261
8. Kirchdoerfer RN, Cotrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, Corbett KS, Graham BS, Mcellan JS, Ward AB (2016) Pre-fusion structure of a human coronavirus spike protein. Nature 531(7592):118–121
9. Walls AC, Tortorici MA, Bosch B-J, Frenz B, Rottier PJ, DiMaio F, Rey FA, Veesler D (2016) Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531(7592):114–117
10. Beniac DR, Andonov A, Grudeski E, Booth TF (2006) Architecture of the sars coronavirus prefusion spike. Nat Struct Mol Biol 13(8):751–752
11. Li F, Berardi M, Li W, Farzan M, Dormitzer PR, Harrison SC (2006) Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain. J Virol 80(14):6794–6800
12. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the sars coronavirus. Nature 426(6965):450–454
13. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L et al (2020) Structure of the sars-cov-2 spike receptor-binding domain bound to the ace2 receptor. Nature 581(7807):215–220
14. Wan Y, Shang J, Graham R, Baric RS, Li F (2020) Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of sars coronavirus. J Virol 94(7):00127–20
15. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L (2020) Characterization of the receptor-binding domain (rbd) of 2019 novel coronavirus: implication for development of rbd protein as a viral attachment inhibitor and vaccine. Cellular & Molecular Immunology, 1–8
16. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A et al (2020) Sars-cov-2 cell entry depends on ace2 and tnrsps2 and is blocked by a clinically proven protease inhibitor. Cell 181:271–280
17. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (2020) The proximal origin of sars-cov-2. Nature Medicine, 1–3
18. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F (2020) Structural basis of receptor recognition by sars-cov-2. Nature 581(7807):221–224
19. Li F, Li W, Farzan M, Harrison SC (2005) Structure of sars coronavirus spike receptor-binding domain complexed with receptor. Science 309(5742):1864–1868
20. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, et al (2020) Crystal structure of the 2019-ncov spike receptor-domain bound with the ace2 receptor. bioRxiv
21. Šali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234(3):779–815. https://doi.org/10.1006/jmbi.1993.1626
22. Krieger E, Nabuurs SB, Vriend G (2003) Homology modeling. Methods Biochem Anal 44:509–524
23. Lai HT, Nguyen DM, Nguyen TT et al (2020) Homology modeling of mouse nrp3 nacht protein domain and molecular dynamics simulation of its apt binding properties. Int. J. Mod. Phys. C (IJMPC) 31(03):1–11
24. Thompson JD, Gibson TJ, Higgins DG (2003) Multiple sequence alignment using clustalw and clustalx. Curr Protoc Bioinformatics 1:2–3
25. Mount DW (2008) Using blossom in sequence alignments. Cold Spring Harbor Protoc 2008(6):39
26. Jo S, Kim T, Iyer VG, Im W (2008) Charmm-gui: a web-based graphical user interface for charm. J Comput Chem 29(11):1859–1865
27. Hansson T, Oostenbrink C, van Gunsteren W (2002) Molecular dynamics simulations. Curr Opin Struct Biol 12(2):190–196
28. Berendsen HJ, van der Spoel D, van Drunen R (1995) Gromacs: A message-passing parallel molecular dynamics implementation. Comput Phys Commun 91(1-3):43–56
29. Huang J, MacKerell AD Jr (2013) Charmm36 all-atom additive protein force field: Validation based on comparison to nmr data. J Comput Chem 34(25):2135–2145
30. Kirschner KN, Yongye AB, Tschampel SM, González-Outeiriño J, Daniels CR, Foley BL, Woods RJ (2008) Glycam06: a generalizable biomolecular force field. carbohydrates. Journal of Computational Chemistry 29(4), 622–655
31. Sun Y, Kollman PA (1995) Hydrophobic solvation of methane and nonbond parameters of the tip3p water model. J Comput Chem 16(9):1164–1169
32. Darden T, York D, Pedersen L (1993) Particle mesh ewald: An n·log(n) method for ewald sums in large systems. J. Chem. Phys. 98(12):10089–10092
33. Hess B, Bekker H, Berendsen HJ, Fraaije JG (1997) Lincs: a linear constraint solver for molecular simulations. J. Comput. Chem. 18(12):1463–1472
34. Hoover WG (1985) Canonical dynamics: Equilibrium phase-space distributions. Phys. Rev. A 31(3):1695
35. Nosé S (1984) A molecular dynamics method for simulations in the canonical ensemble. Mol. Phys. 52(2):255–268
36. Hünenberger PH (2005) Thermostat algorithms for molecular dynamics simulations. In: Advanced Computer Simulation, pp. 105–149. Springer
37. Parrinello M, Rahman A (1981) Polymorphic transitions in single crystals: A new molecular dynamics method. J. Appl. Phys. 52(12):7182–7190
38. Martyna GI, Tobias DJ, Klein ML (1994) Constant pressure molecular dynamics algorithms. J Chem Phys 101(5):4177–4189
39. Humphrey W, Dalke A, Schulten K (1996) Vmd: visual molecular dynamics. J Mol Graph 14(1):33–38
40. Miller BRIII, McGee, TDFr, Swails JM, Homeyner N, Gohlke H, Rötterg AE (2012) Mmpbsa. py: an efficient program for endstate free energy calculations. J. Chem. Theory Comput. 8(9), 3314–3321
41. Salomon-Ferrer R, Case DA, Walker RC (2013) An overview of the amber biomolecular simulation package. Wiley Interdiscip. Rev.: Comput. Mol. Sci. 3(2):198–210
42. DasGupta D, Mandalaparthy V, Jayaram B (2017) A component analysis of the free energies of folding of 35 proteins: A consensus view on the thermodynamics of folding at the molecular level. J Comput Chem 38(32):2791–2801
43. Walls AC, Park Y-I, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function, and antigenicity of the sars-cov-2 spike glycoprotein. Cell 181(2):281–292
44. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLeLLan JS (2020) Cryo-em structure of the 2019-ncov spike in the prefusion conformation. Science 367(6483):1260–1263
45. Spinello A, Saltalamacchia A, Magistrato A (2020) Is the rigidity of sars-cov-2 spike receptor-binding motif the hallmark for its enhanced infectivity? insights from all-atom simulations. J. Phys. Chem. Lett. 11(12):4785–4790
46. Jafary F, Jafari S, Ganjalikhany MR (2021) In silico investigation of critical binding pattern in sars-cov-2 spike protein with angstotensin-converting enzyme 2. Sci Rep 11(1):1–13
47. Ghorbani M, Brooks BR, Klauda JB (2020) Critical sequence hotspots for binding of novel coronavirus to angiotensin convertor enzyme as evaluated by molecular simulations. J Phys Chem B 124(45):10034–10047
48. Pavlova A, Zhang Z, Acharya A, Lynch DL, Pang YT, Mou Z, Parks JM, Chipot C, Gumbart JC (2021) Machine learning reveals the critical interactions for sars-cov-2 spike protein binding to ace2. J. Phys. Chem. Lett. 12:5494–5502
49. Han Y, Král P (2020) Computational design of ace2-based peptide inhibitors of sars-cov-2. ACS nano 14(4):5143–5147
50. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q (2020) Structural basis for the recognition of sars-cov-2 by full-length human ace2. Proc Natl Acad Sci USA 117(52):34662–34665
51. Chen Y, Guo Y, Pan Y, Zhao J (2020) Structure analysis of the free energies of folding of 35 proteins: A consensus view on the thermodynamics of folding at the molecular level. J Comput Chem 38(32):2791–2801
52. Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, Lu X, Zhang Y, Ma L, Gu W et al (2020) Key residues of the receptor binding motif in the spike protein of sars-cov-2 that interact with ace2 and neutralizing antibodies. Cell Mol Immunol 17(6):621–630

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.